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refoil factor (TFF)1 is synthesized and secreted by the
normal stomach mucosa and by the gastrointestinal
cells of injured tissues. The link between mouse TFF1
inactivation and the fully penetrant antropyloric tumor
phenotype prompted the classiﬁcation of TFF1 as a gastric
tumor suppressor gene. Accordingly, altered expression,
deletion, and/or mutations of the TFF1 gene are frequently
observed in human gastric carcinomas. The present study
was undertaken to address the nature of the cellular and
molecular mechanisms targeted by TFF1 signalling. TFF1
effects were investigated in IEC18, HCT116, and AGS gas-
trointestinal cells treated with recombinant human TFF1,
and in stably transfected HCT116 cells synthesizing consti-
tutive or doxycycline-induced human TFF1. We observed
T
 
that TFF1 triggers two types of cellular responses. On one
hand, TFF1 lowers cell proliferation by delaying G1-S cell
phase transition. This results from a TFF1-mediated increase
in the levels of cyclin-dependent kinase inhibitors of both
the INK4 and CIP subfamilies, leading to lower E2F tran-
scriptional activity. On the other hand, TFF1 protects cells
from chemical-, anchorage-free–, or Bad-induced apoptosis.
In this process, TFF1 signalling targets the active form of
caspase-9. Together, these results provide the ﬁrst evidence
of a dual antiproliferative and antiapoptotic role for TFF1.
Similar paradoxical functions have been reported for tumor
suppressor genes involved in cell differentiation, a function
consistent with TFF1.
 
Introduction
 
Trefoil factor (TFF)*1 (pS2) is a small secreted protein. It
belongs to the TFF protein family that is characterized by a
clover leaf–like disulphide structure named the TFF domain
(Thim, 1997; Ribieras et al., 1998; Hoffmann et al., 2001).
This domain, highly conserved from amphibians to mam-
mals, is likely to have an important function. In mammals,
two other TFFs have been identified, TFF2 (spasmolytic
polypeptide [SP]) and TFF3 (intestinal trefoil factor [ITF]).
TFFs are normally synthesized in the gastrointestinal mucosa.
In addition to transcriptional regulation via the Gata 4 and
HNF3 factors (Beck et al., 1999), the tissue-specific expres-
sion of TFFs along the gastrointestinal tract is dependent on
the methylation status of their proximal promoter regions
(Ribieras et al., 2001).
In mouse embryos, TFF1 starts to be expressed at day 17
 
in the epithelial cells lining the surface and the nascent stomach
pits and glands. In addition, 18-d embryos show expression of
TFF1 in the glands of the gastroduodenal junction corre-
 
sponding to the developing Brunner’s glands. This latter
expression of TFF1 is no longer observed beyond postnatal
 
day 14 (Lefebvre et al., 1993; Otto and Patel, 1999). In
human and mouse adult tissues, TFF1 expression is normally
restricted to the stomach. TFF1 is observed in the fundus,
antrum, and antrumpyloric mucosa. It is located in the epi-
thelial cells of the upper part of the pits, an area where cells
undergo commitment and differentiate to give rise to a func-
tional secreting mucosa and to limit gland proliferation.
TFF1 is observed in the cytoplasm of producing cells with a
preferential perinuclear accumulation, a subcellular localiza-
tion appropriate for a secreted protein. Accordingly, TFF1 is
detected in the gastric juice and urine (Rio et al., 1988).
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In ulcerative and acute inflammatory bowel diseases such
as Crohn’s disease, duodenal peptic ulcer, or hemorrhagic
rectocolitis, TFF1 is ectopically expressed along the entire
human gastrointestinal tract. TFF1 is observed in cells of
regenerating tissues surrounding areas of damage (Rio et al.,
1991; Wright et al., 1993). These observations raised the
possibility that TFF1 might be involved in the repair pro-
cess and the maintenance of mucosal integrity. In this con-
text, transgenic mice overexpressing human TFF1 in the je-
junum have a lower rate of induced ulceration in this part
of the gastrointestinal tract, showing that TFF1 exerts a
protective effect (Playford et al., 1996). It has been shown
that stable expression of TFF1 promotes invasiveness of hu-
man colonic HCT8/S11 cells and cell scattering (Emami et
al., 2001). Because the TFF domain of TFF1 is able to di-
rectly interact with the von Willebrand factor C cysteine-
rich domains of mucins (Tomasetto et al., 2000), TFF1
might also protect the gastrointestinal tract through its par-
ticipation in the formation of the mucus layer covering all
of the gastrointestinal mucosa. Together, these in vitro and
in vivo data suggest that TFF1 could serve as a valuable
pharmacological tool for the prevention and healing of gas-
trointestinal tissue ulcerations.
Using transgenic mice overexpressing human TFF1 in the
mammary gland, it has been shown that TFF1 does not fa-
vor cell proliferation and is not an oncogene (Tomasetto et
al., 1989). In contrast, 100% of TFF1-null mice exhibit
antropyloric hyperplasia and displasia, leading to adenoma-
tous tumors with occasional foci of intraepithelial or intra-
mucosal carcinoma. Thus, at least in the stomach, TFF1 acts
as a tumor suppressor gene (Lefebvre et al., 1996). Accord-
ingly, 50% of human gastric tumors are devoid of TFF1
(Luqmani et al., 1989). TFF1 gene deletion and alterations
(Park et al., 2000a, 2000b) as well as abnormal gene methyl-
ation (Fujimoto et al., 2000) have been reported to be asso-
ciated to gastric tumors. Finally, a recent report showed that
TFF1 induces growth inhibition in the human AGS gastric
adenocarcinoma cell line (Calnan et al., 1999).
How TFF1 acts at the molecular and cellular levels re-
mains elusive. Tumor suppressors have been shown to exert
various functions to either lower cell proliferation, increase
cell death, or favor cell differentiation (Kinzler and Vogel-
stein, 1998). Therefore, TFF1 might be involved in such
processes. In the present study, we address these hypotheses
in the IEC18, HCT116, and AGS gastrointestinal cell lines
treated with recombinant human TFF1, and in HCT116
cells stably transfected with vectors allowing either constitu-
tive or induced expression of human TFF1.
 
Results
 
TFF1 treatment or expression lowers gastrointestinal 
cell number
 
We first tested the effect of TFF1 on the viability of gas-
trointestinal rat IEC18 (diploid intestinal cells), and human
HCT116 (colon cancer), and AGS (gastric cancer) cells, that
do not express endogenous TFF1. The addition of increas-
ing quantities (0.1–50 
 
 
 
M) of recombinant human TFF1
(Kannan et al., 2001) in the culture medium lowered, in a
dose-dependent manner, the cell number of these cell lines
(MTT test) (Fig. 1). This effect was already observed at 0.1
 
 
 
M TFF1. The maximum decrease in cell number was 20%
for IEC18, 25% for HCT116, and 30% for AGS cells.
Moreover, this effect was TFF1 specific, as the addition of
albumin or of an unrelated peptide at the same concentra-
tion did not alter cell number (unpublished data). Similar
experiments were performed using the human HeLa (cervix)
and Jurkat (T cell) cancer cell lines. In the latter case, no al-
teration in cell number was observed after TFF1 treatment
(Fig. 1), indicating that the decrease observed in the IEC18,
HCT116, and AGS cells was cell specific and did not result
from a nonspecific cytotoxic effect of the recombinant hu-
man TFF1. Moreover, because IEC18 cells are nontrans-
formed cells, TFF1 function is not due to cell malignancy.
Finally, human TFF1 can exert effects on rat IEC18 cells,
showing that the TFF1 signalling pathway has been well
conserved during species evolution.
In vivo, TFF1 is expressed in response to injury in intes-
tine and colon (Rio et al., 1991). Thus, to further study
TFF1 function, we established, in the human colon cancer
cell line HCT116, clones constitutively expressing human
TFF1 (HCT116/TFF1) (Fig. 2, lanes 3 and 4), and clones
expressing the human TFF1 under doxycycline induction
(HCT116/iTFF1) (Fig. 2, lanes 11 and 12). HCT116/
CMV (Fig. 2, lanes 1 and 2) and HCT116/UHD clones
(Fig 2, lanes 5, 6, 9, and 10), transfected with vector alone,
were used as a negative control. Moreover, in order to avoid
doxycycline-specific effects (Fife et al., 1997), HCT116/
UHD clones grown in the presence of doxycycline were also
used as negative controls in all of the following experiments.
Constitutive or induced TFF1 expression significantly re-
duced the number of viable cells to 
 
 
 
20 (83 
 
  
 
6.2% vs.
100%, 
 
P 
 
 
 
 0.01) and 30% (68 
 
  
 
7.1% vs. 100%, 
 
P 
 
 
 
0.01) of control levels, respectively.
Together, these results indicate that TFF1 lowers gas-
trointestinal cell number in both a paracrine and autocrine
manner, and suggest a possible role for TFF1 in the regula-
tion of either cell proliferation or cell death.
Figure 1. Human recombinant TFF1 decreases IEC18, HCT116 and 
AGS gastrointestinal cell numbers. The number of live cells was 
estimated by the MTT method. Human recombinant TFF1 addition to 
the culture medium (0.1–50  M) induces a dose-dependent reduction 
in the number of HCT116 ( ), IEC18 ( ) and AGS (cross) cells but 
has no effect on that of hematopoietic Jurkat ( ) and cervix HeLa ( ) 
cells. Standard deviations are indicated. *P   0.05; **P   0.01. 
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TFF1 delays G1-S phase transition
 
Therefore, we investigated the effect of TFF1 on the cell cycle.
Addition of recombinant human TFF1 to parental HCT116
cells led to a slight increase in the number of cells in G1 phase,
suggesting that TFF1 might delay the passage of cells to S phase
(unpublished data). This hypothesis was further studied using
G1-enriched parental HCT116 cells (85% of cells in G1 phase,
4% in S, and 11% in G2/M). In the absence of TFF1 treat-
ment, after a 1-h release into cell cycle, 42% of the cells (34% S
and 8% G2/M) had passed through the G1-S checkpoint. In
contrast, TFF1 treatment (1 
 
 
 
M) resulted in only 19% of the
cells (16% S and 3% G2/M) proceeding through the G1/S
transition. Thus, under these conditions, TFF1 cell treatment
diminishes by 50% the S phase cell entry (Fig. 3). Similar ex-
periments were performed using G1-enriched TFF1-trans-
fected HCT116 cell lines expressing either constitutive or in-
ducible (Table I) TFF1. Whereas control clones (HCT116/
CMV and HCT116/UHD) showed 
 
 
 
50% of the cells in S
and G2/M phases, constitutive (HCT116/TFF1 clones) or
doxycycline-induced (HCT116/iTFF1 clones) TFF1 expres-
sion led to 
 
 
 
30 and 40% of cells in S and G2/M phases, re-
spectively. Thus, constitutive and doxycycline-induced TFF1
expression reduce S phase entry by 40 and 20%, respectively.
Consistent with the higher number of cells in G1 phase,
FACS screening analyses (Table I) showed that the number
of cells positive for cyclin D1, a cell cycle protein specific of
the G1 phase, was increased in the presence of TFF1 (1.4- to
2.5-fold). In contrast, TFF1 led to a decrease of cell cycle
proteins expressed later in the cell cycle such as PCNA (S
phase) (1.5- to 30-fold) and cyclin B1 (G2 phase) (1.2- to 9-
fold).
Thus, in both a paracrine and autocrine manner, TFF1 re-
tains cells within the G1 phase of the cell cycle, thereby de-
laying their S phase entry and reducing their proliferation.
 
TFF1 leads to increased expression of cyclin-dependent 
kinase inhibitors
 
By controlling the level of cyclin-dependent kinase (cdk) ac-
tivity, cdk regulators control cell cycle commitment (Malum-
bres and Barbacid, 2001). Thus, overexpression of the cdk
activator cyclin D1 favors the passage of cells through G1
and promotes proliferation. However, in our experiments, S
phase transition is repressed in the presence of TFF1 despite
Figure 2. Western blot analysis of constitutive and doxycycline-
induced TFF1 synthesis in stably transfected HCT116 cell lines. 10 
 l of conditioned culture medium from two clones of each HCT116 
cell line were loaded. TFF1 detection was done using the p2802 
specific antibody. (Lanes 1 and 2) pCMV-transfected control clones. 
(Lanes 3 and 4) Clones transfected with the pCMV-hTFF1 constitutive 
expression vector. (Lanes 5, 6, 9, and 10) pUHD-transfected control 
clones. (Lanes 7, 8, 11, and 12) Clones transfected with the pUHD-
hTFF1 inducible vector. (Lanes 5–8) Absence (Dox.  ) of doxycycline 
treatment. (Lanes 9–12) Presence (Dox.  ) of doxycycline treatment. 
(Lanes 13–15) 5, 10, and 50 ng of human recombinant TFF1. 
Molecular weight scale is indicated on the left in kD.
Figure 3. TFF1 induces the accumulation of cells in the G1 phase 
of the cell cycle.  Analysis of the cell cycle patterns was done using 
propidium iodide. Cell cycle profiles of G1-enriched HCT116 
parental cells after a 1 hour release into the cell cycle in the absence 
(control)  or presence (TFF1, 1  M) of human recombinant TFF1 
(1 M). Cells in the G1 (M1), S (M2), and G2/M (M3) phases are 
indicated. TFF1 delays G1/S transition.
 
Table I. 
 
Percentage of cells in G1, S, and G2/M phases, and positive for cyclin D1, PCNA, and cyclin B1 proteins after TFF1 treatment and 
constitutive or induced TFF1 expression
Cell cycle TFF1 treatment Constitutive Inducible
 
 
 
a
 
 
 
b
 
P
 
  
 
P
 
  
 
P
 
Phase 
 
G1 58 
 
  
 
1.9 81 
 
  
 
2.1
 
 
 
0.01 49 
 
  
 
3.4 72 
 
  
 
4.0 
 
 
 
0.01 50 
 
  
 
2.6  61 
 
  
 
2.5
 
 
 
0.01
S 34 
 
  
 
2.2 16 
 
  
 
2.5
 
 
 
0.01 38 
 
  
 
3.7 23 
 
  
 
3.3
 
 
 
0.01 40 
 
  
 
1.3   28 
 
  
 
1.5 
 
 
 
0.01
G2/M 8 
 
  
 
1.6 3 
 
  
 
0.7
 
 
 
0.01 13 
 
  
 
1.7   5 
 
  
 
0.8
 
 
 
0.01 10 
 
  
 
1.1 11 
 
  
 
1.2 NS
 
Protein
 
D1 8 
 
  
 
1.2 20 
 
  
 
5.7
 
 
 
0.01 12 
 
  
 
3.6 17 
 
  
 
0.7 NS   8 
 
  
 
1.9 16 
 
  
 
1.6
 
 
 
0.01
PCNA 62 
 
  
 
2.5 2 
 
  
 
0.6
 
 
 
0.01 56 
 
  
 
10.2  30 
 
  
 
6.2
 
 
 
0.05 50 
 
  
 
2.3 34 
 
  
 
5.6
 
 
 
0.01
B1 5 
 
  
 
1.6 1 
 
  
 
0.8
 
 
 
0.01  6 
 
  
 
2.5 5 
 
  
 
2.1 NS  9 
 
  
 
1.2   1 
 
  
 
0.6
 
 
 
0.01
 
a
 
 
 
, Absence of TFF1 treatment or synthesis.
 
b
 
 
 
, Presence of TFF1 treatment or synthesis. 
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the observation that cyclin D1 levels were increased. This ob-
servation suggests that higher levels of cyclin D1 reflect the
higher number of cells in G1, and that cdk inhibitors that
negatively regulate the cell cycle (Ekholm and Reed, 2000)
might be involved in TFF1 signalling. Therefore, the expres-
sion of two cdk  of the INK4 family, p15 and p16, and two
cdk inhibitors of the CIP family, p21 and p27, were studied
by flow cytometry. All data obtained from the three condi-
tions, TFF1 treatment, constitutive, and induced TFF1 ex-
pression, are compiled in Table II. Upon TFF1 treatment or
expression, most of the cell lines showed significantly in-
creased levels of p15 (1.5- to 2.5-fold), p16 (1.4-fold), p21
(1.4- to 2.3-fold), and p27 (1.4- to 2.5- fold).
Thus, the presence of TFF1 resulted in the upregulation
of all cdk inhibitors studied, indicating that TFF1 delays the
G1-S phase transition via cdk inhibitors of both INK4 and
CIP subfamilies.
 
TFF1 increases pRb activity and decreases E2F activity
 
The retinoblastoma protein pRb, a target of cdk, is a major
player in the G1-S cell transition (Weinberg, 1995; Herwig
and Strauss, 1997; Ross et al., 1999). pRb activity during the
cell cycle is regulated in a phosphorylation-dependent man-
ner. In order to test whether TFF1 affects this protein, we
studied the level of pRb expression and activity in response to
TFF1. FACS analysis showed a significant increase in pRb ex-
pression in all cases: TFF1 treatment (15 
 
  
 
1.2 to 31
 
   
 
4.6,
 
P 
 
  
 
0.01), constitutive TFF1 (18
 
   
 
1.5 to 53
 
   
 
4.5, 
 
P 
 
 
 
0.01), and inducible TFF1 expression (4
 
   
 
0.8 to 14
 
   
 
4.5,
 
P 
 
  
 
0.01). Transcriptional activity of pRb was then investi-
gated by cotransfecting cells with a luciferase reporter gene
under the control of regulatory promoter regions shared by
genes responding to pRb (pRb-Ta-Luc). TFF1 treatment of
the parental HCT116 cells led to a twofold increase in pRb
activity (Fig. 4). Similarly, in stably transfected HCT116 cell
lines expressing TFF1, pRb activity was increased about 2.5-
fold (Fig. 4). These results indicate that the pRb synthesized
in response to TFF1 is transcriptionally active.
The transcription factor E2F is a major regulatory factor de-
termining entry into S phase. Its interaction with the unphos-
phorylated form of pRb gives rise to pRb/E2F heterodimers,
leading to decreased E2F transcriptional activity, and prevents
cells from entering S phase (Herwig and Strauss, 1997; Ross et
al., 1999). Therefore, the effect of TFF1 on E2F transcrip-
tional activity was investigated in HCT116 cell lines trans-
fected with a luciferase reporter gene under the control of a
Figure 4. TFF1 modifies pRb and E2F 
transcriptional activity. Parental 
HCT116- and HCT116-expressing TFF1 
constitutively or under induction were 
transfected with vectors containing a 
specific response element for pRb 
(pRb-Ta-Luc) or E2F (pE2F-Ta-Luc) 
upstream from a TATA-like promoter 
driving a luciferase reporter gene. The 
pTA-Luc vector was used as a negative 
control. Luciferase activities were 
corrected for  -galactosidase activities. 
pTA-Luc luciferase activity was set at 1. TFF1 treatment (10  M), constitutive or inducible TFF1 synthesis increased pRb transcriptional activity and 
decreased E2F transcriptional activity. (Gray bars) Absence of TFF1. (White bars) Presence of TFF1. Standard deviations are indicated. **P   0.01.
Figure 5. TFF1 prevents induced apoptosis of IEC18, HCT116, 
and AGS gastrointestinal cells. Apoptosis was induced by treat-
ment with 5 mM sodium butyrate (But), 50  M ceramide (Cer), 
anchorage-free condition (Anc), or Bad expression (Bad), as 
indicated. The number of live cells was estimated by the MTT 
method. Independent of the nature of the apoptosis inducer, 
addition of recombinant TFF1 (0.1 to 10  M) protected gastrointestinal 
IEC18 (top), HCT116 (middle) and AGS (bottom) cells from 
apoptosis in a dose-dependent manner. Standard deviations 
are indicated. *P   0.05; **P   0.01. Antiproliferative and antiapoptotic TFF1 functions | Bossenmeyer-Pourié et al. 765
regulatory promoter region shared by genes responding to
E2F (pE2F-Ta-Luc). The level of luciferase expression was ap-
proximately twofold lower in the presence of TFF1, indicating
that TFF1 leads to a twofold decrease in E2F activity (Fig. 4).
Thus, TFF1 delays HCT116 cells from entering S phase
of the cell cycle, at least partially, via a reduction in E2F
transcriptional activity.
TFF1 reduces gastrointestinal cell-induced apoptosis
In addition to studying the effect of TFF1 on prolifera-
tion, we also investigated the possible role of TFF1 in ap-
optosis. Although reduced in number (Fig. 1), TFF1-
treated or -expressing cells appeared healthy, with no
morphological evidence of cell death (unpublished data).
However, as another member of the TFF family was re-
ported to have antiapoptotic properties (Kinoshita et al.,
2000), the effect of TFF1 was also tested on apoptotic
cells. Apoptosis was induced using either C2-ceramide
(IEC18, HeLa), butyrate (HCT116 and AGS), stauro-
sporine (Jurkat), Bad expression (IEC18, HCT116, and
AGS), or anchorage-free conditions (IEC18, HCT116,
and AGS). The number of viable IEC18, HCT116 and
AGS cells decreased dramatically (30–75%) regardless of
the nature of the apoptotic stimulus (Fig. 5). The most ef-
fective inducer of apoptosis was the anchorage-free condi-
tion (60–75% cell death).
The simultaneous addition of increasing concentrations
of recombinant human TFF1 (0.1–10  M) to apoptotic
inducers reduced the magnitude of the apoptosis. This an-
tiapoptotic effect first detected at 0.1  M TFF1 was opti-
mal at 10  M TFF1, and was more pronounced in
HCT116 and AGS than in IEC18 cells (Fig. 5). Similarly,
Figure 6. TFF1 reduces caspase 
activities. Apoptosis of HCT116 cells 
was induced using either 5 mM sodium 
butyrate treatment (A), anchorage-free 
condition (B), or Bad expression (C). 
Enzymatic activities of caspase-1, -2, -3, 
-4/5, -6, -8, and -9 (C1 to C9) were 
investigated by quantification of the 
cleavage of specific fluorometric sub-
strates. Results were given as fold in-
crease compared with controls. TFF1 
treatment (10  M), constitutive or 
induced TFF1 expression reduces activity 
of several caspases. (Gray bars) Absence 
of TFF1. (White bars) Presence of TFF1. 
Standard deviations are indicated. 
*P   0.05; **P   0.01.
Table II. TFF1 treatment and constitutive and induced TFF1 expression induce increased levels of cdk inhibitors
Ckis TFF1 treatment Constitutive Inducible
   P    P    P
INK4
P15 2   0.8 5   0.2  0.01 15   4.1 37   3.5  0.01 17   0.4 18   0.5 NS
P16 44   6.1 61   2.3  0.05 50   2.5 64   1.8  0.05 37   2 46   1.5  0.05
CIP
P21 3   17    1.1  0.05 14   3.5 20   4.5 NS 11   0.5 19   1.5  0.05
P27 13   1.3  18   0.8  0.05 3   0.2 5   1.5  0.05 3   18     1.5  0.05766 The Journal of Cell Biology | Volume 157, Number 5, 2002
transfected HCT116 cells expressing constitutive (65  
6.2% vs. 50   6.2% viable cells, P   0.01), or inducted
(67   6.7% vs. 54   4.6% viable cells, P   0.05) TFF1
were less sensitive to butyrate-induced apoptosis than con-
trol cells. We noted that, for the doxycycline-induced
TFF1, this represents a complete abolishment of the bu-
tyrate-induced apoptosis, as we previously observed that
TFF1 expression alone reduces the cell number by  30%
(see first paragraph). TFF1 inhibition of induced apoptosis
was not observed for the nongastrointestinal HeLa and Jur-
kat cells (unpublished data).
Thus, TFF1 treatment or synthesis prevents chemical-, Bad-,
or anchorage-free–induced gastrointestinal cell apoptosis.
TFF1 decreases caspase-3, -6, -8, and -9 activities
Because apoptotic signals converge on the caspase cascade,
the activities of caspase-1, -2, -3, -4/5, -6, -8, and -9 were
investigated in HCT116 cell lines (Fig. 6). Butyrate-
induced apoptosis of parental HCT116 cells led to an in-
crease in the activities of caspase-2 (twofold), -3 (fivefold),
-6 (threefold), and -9 (twofold), whereas there was no
modification of caspase-1, -4/5, and -8 activities. Addi-
tion of TFF1 (10  M) almost completely inhibited bu-
tyrate-induced caspase-3 and -6 activities, and partially re-
duced caspase-9 activity, but had no effect on caspase-2.
Anchorage-free conditions led to increased activity of all
the caspases studied: caspase-1 (twofold), -2 (threefold),
-3 (threefold), -4/5 (threefold), -6 (twofold), -8 (twofold),
and -9 (3.5-fold). TFF1 treatment completely abolished
the induced activity of caspase-6 and -8, and partially re-
duced that of caspase-3 and -9. However, TFF1 treatment
had no obvious effect on caspase-1, -2, and -4/5 activities.
Finally, Bad expression led to an increase in caspase-3 (2.5-
fold), -6 (twofold), and -9 (twofold) activities that were
totally abolished by TFF1 treatment. Similar results were
observed in the apoptotic TFF1-transfected HCT116 cell
lines. Both constitutive and doxycycline-induced TFF1
expression significantly reduced caspase-3, -6, -8, and -9
activities (Fig. 6). In the absence of apoptosis induction,
TFF1 treatment of parental cells (10  M) did not modify
the basal level of any of the caspase activities tested (un-
published data).
Thus, the antiapoptotic function of TFF1 occurs via the
decrease of caspase-3, -6, -8, and -9 activities.
TFF1 does not prevent procaspase-9 activation
Caspases are produced from inactive procaspase forms that
are activated by proteolytic cleavage by other caspases, lead-
ing to the caspase cascade. Caspase-9, an initiator of this cas-
cade, is processed at the level of the apoptosome (Slee et al.,
1999). We checked if TFF1-reduced activity of caspase-9
was due to a TFF1-induced inhibition of its proteolytic acti-
vation. The effect of TFF1 on the cleavage of pro-caspase-9
was studied by Western blot analysis of butyrate-treated cell
extracts using an antibody that recognizes both the inactive
procaspase-9 (47 kD) and the active caspase-9 (37 kD). Nei-
ther TFF1 treatment (10  M) of parental HCT116 cells
(Fig. 7, lane 4), nor constitutive or induced TFF1 in trans-
fected HCT116 cells (Fig. 7, lanes 6 and 8) reduced the
quantity of mature caspase-9.
Together, these results indicate that TFF1 does not inhibit
the processing of the inactive pro-caspase-9 to the active form.
Discussion
From in vivo and in vitro data, a tumor suppressor function
has been proposed for TFF1 (Lefebvre et al., 1996; Calnan et
al., 1999). In the present study, we investigated in IEC18,
HCT116, and AGS gastrointestinal cells the possible involve-
ment of TFF1 in regulating cell proliferation and cell death.
TFF1 exerts an antiproliferative effect via the 
pRb/E2F pathway
We have demonstrated that TFF1 represses cell progres-
sion towards the S phase of the cell cycle, and therefore
proliferation. The transition between the G1 and S phase
is tightly regulated (Herwig and Strauss, 1997; Ross et al.,
1999; Malumbres and Barbacid, 2001; Zheng and Lee,
2001). At this checkpoint, a decision is made by the cell
whether to proceed or not. pRb and E2F are major players
in a regulatory circuit in the late G1 phase. E2F triggers S
phase entry by activating promoters of S phase–regulated
genes. A prerequisite for the pRb growth-suppressor func-
tion is binding of its unphosphorylated form to the E2F
transcription factor, thus inhibiting E2F transcriptional
activity, and arresting cells in G1. Consistently, the pres-
ence of TFF1 leads to a twofold increase in pRb activity
that is associated with a twofold decrease in E2F tran-
scriptional activity. These observations provide the first
Figure 7. TFF1 does not alter 
procaspase-9 cleavage. Western blot 
analysis of cell extracts (15  g protein) 
from butyrate-treated (But.  ) parental 
(lanes 3 and 4) and stably transfected 
HCT116 cell lines expressing constitutive 
(lane 6) or doxycycline-induced (lane 8) 
TFF1. TFF1 treatment (10  M, TFF1  ) 
was as indicated. (Lane 9) Cleaved 
caspase-9 as positive control. Arrows 
indicate the inactive procaspase-9 (47 
kD) and the active caspase 9 (37 kD). 
TFF1 does not modify procaspase-9 
cleavage. Molecular weight scale is 
indicated on the left in kD. Antiproliferative and antiapoptotic TFF1 functions | Bossenmeyer-Pourié et al. 767
evidence of a relationship between a member of the TFF
family and cell cycle regulation. Moreover, it indicates
that the effector of the antimitotic function of TFF1 is the
pRb/E2F pathway (Fig. 8).
TFF1 signalling pathway targets Cdk inhibitors
Cdks associated with D-type cyclins, are the early executers
that trigger the cell transition to S phase, via phosphoryla-
tion of target proteins including pRb. Our data suggest that
TFF1 reduces the function of these cdks. Accordingly, TFF1
leads to an increased level of cdk inhibitors of both INK4
and CIP subfamilies. Members of the INK4 family (p16,
p15, p18, and p19) specifically bind to cdk4 and inhibit
pRb phosphorylation, thereby causing G1 phase arrest
(Sherr and Roberts, 1999; Ashizawa et al., 2001). Interest-
ingly, loss of p16 has been associated with progression of hu-
man gastric cancer (Myung et al., 2000). The function of
cdk inhibitors of the CIP family (p21, p27, and p57) is
more complex. They display mainly inhibitory activity to-
wards the cyclin E/cdk2 complex which is required for cor-
rect E2F activity, and thus act to block S phase entry. How-
ever, in the absence of INK4 proteins, they can also bind
cyclin D/cdk4 complexes which effectively sequester them,
facilitating cyclin E/cdk2 function. Thus, the reduction of
cell cycle commitment observed in the presence of TFF1 re-
sults from the upregulation of both INK4 and CIP cdk in-
hibitors (Fig. 8). Similarly, TGF  was shown to inhibit G1
cdks through the cooperative action of INK4 and CIP cdk
inhibitors (Reynisdottir et al., 1995).
TFF1 exerts an antiapoptotic function
We observed that TFF1 does not induce apoptosis, as would
be expected for a tumor suppressor gene, but in contrast,
TFF1 was able to reduce induced apoptosis in gastrointestinal
cells. In vivo, various apoptotic pathways are activated de-
pending on the external stimuli. Thus, three types of apopto-
sis were tested. Apoptosis was first induced using butyrate
treatment, whose action has already been reported in colon
cancer cells (Ruemmele et al., 1999). The short-chain fatty
acid (SCFA) butyrate is normally present in the gastrointesti-
nal tract, as it is produced in the lumen of the colon by bacte-
rial fermentation of carbohydrates (Mariadason et al., 2001).
Because epithelial cells require matrix attachment for their
growth, the second type of induced apoptosis was evaluated
by maintaining the cells in anchorage-free conditions. This
type of apoptosis, termed anoikis, causes the release of cyto-
chrome c from mitochondria and is a strong activator of
caspases (Rytomaa et al., 2000). Finally, we induced apoptosis
by expressing Bad (Jan et al., 1999), a member of the Bcl-2
family that acts at the mitochondrial level and leads to the ac-
tivation of procaspase-9. In all cases, TFF1 protected cells
from induced apoptosis. Thus, the antiapoptotic function of
TFF1 is independent of the nature of the apoptotic stimulus,
suggesting that TFF1 signalling targets a common process.
TFF1 targets the active form of caspase-9
Caspases belong to two main subgroups: the initiator
caspases (caspase-2, -8, -9, and -10) that activate procas-
pases, and the effector caspases (caspase-3, -6, and -7) in-
Figure 8. Schematic model of signaling pathways 
mediating TFF1 antiproliferative and anti-apoptotic 
function. Cells integrate external mitogenic or 
antimitogenic stimuli to decide whether or not to 
proliferate. Although the number and the nature of 
the molecular mechanisms participating in trans-
duction of the external TFF1 stimulus remain 
unknown (?), we demonstrate that TFF1 triggers 
two types of responses. One function of TFF1 is 
to delay cell cycle commitment. TFF1 signaling 
results in increased levels of INK4 and CIP cdk 
inhibitors. Increased amounts of INK4 alter the 
distribution of cdk4 in favor of INK4/cdk4 and 
thereby reverse the sequestration of CIP. The 
release of CIP proteins leads to cyclinE/cdk2 
inhibition, and a lower rate of pRb phosphorylation. 
This event results in the formation of pRb/E2F 
complexes, and subsequently, to the reduction 
of E2F transcriptional activity and reduced expression 
of E2F-responsive genes needed to drive cells 
through the G1/S transition. On the other hand, 
TFF1 signaling targets the active caspase-9, 
possibly via inhibitors of the IAP family, thereby 
down-regulating apoptosis. Apopt: apoptosome; 
C9, caspase-9; D and E, cyclins D and E; ext and 
int: extra- and intracellular.768 The Journal of Cell Biology | Volume 157, Number 5, 2002
volved in the cleavage of various substrates essential for the
life of the cell (Nunez et al., 1998). Caspase-1, -4, and -5 are
peculiar, as they mainly mediate inflammatory signals. In
our apoptosis-induced systems, TFF1 was found to partially
or completely block caspase-3, -6, -8, and -9 activities, but
had no effect on caspase-1, -2, and -4/5 activities. This indi-
cates that TFF1 specifically targets only some caspases. A
study of the kinetics of caspase synthesis during the anoikis
process induced in normal human intestinal epithelial cells
showed that the alteration of caspase-9 alone may lead to the
inactivation of caspase-3, -6, and -8 (Grossmann et al.,
2001). This scheme calls into question the number and the
nature of caspases inhibited by TFF1. In any case, our data
indicate that caspase-9, which is upstream in the caspase cas-
cade (Slee et al., 1999), is a target of TFF1 signalling. More-
over, we demonstrated that TFF1 does not inhibit pro-cas-
pase-9 processing (Fig. 8). Thus, it is tempting to speculate
that the TFF1 pathway might target specific inhibitor(s) of
the active form of caspase-9, such as inhibitors of apoptosis
(IAP) and related proteins (Datta et al., 2000).
TFF1, a factor for gastrointestinal cell differentiation
Together, our results demonstrate that TFF1 has a complex
role in that it is not only a potent inhibitor of proliferation, but
also an efficient inhibitor of apoptosis. Similar dual and para-
doxical functions have already been reported for tumor sup-
pressor genes involved in cell differentiation. In this context,
pRb, which is essential for correct retina ontogenesis, has been
shown to block cells in G1 of the cell cycle and inhibit subse-
quently induced apoptosis signals (Herwig and Strauss, 1997;
Ross et al., 1999; Zheng and Lee, 2001). The gastrointestinal
mucosa is a tissue that has a high rate of cell turnover (Karam,
1999). Therefore, TFF1 represents an important player in reg-
ulating the balance between gastrointestinal cell proliferation,
death, and differentiation. Consistently, in HT29-MTX and
Caco2 models of differentiation, TFF1 expression occurs when
cells reach confluency and start to differentiate (Gouyer et al.,
2001; unpublished data). Interestingly, Caco2 cell differentia-
tion was reported to involve a relative G1/S block associated
with the suppression of cdk2 and cdk4 activities (Ding et al.,
1998), increased pRb and decreased E2F activities; p21 and
p27 cdk inhibitors are also directly implicated (Deschenes et
al., 2001). Finally, confluent Caco2 cells become butyrate in-
sensitive and apoptosis levels are stable (Mariadason et al.,
2001). A TFF1 function as a differentiation factor is also con-
sistent with in vivo observations. Actually, TFF1 is crucial for
correct gastric ontogenesis, and is expressed in differentiated
gastrointestinal cells (Ribieras et al., 1998). Moreover, its defi-
ciency is associated with human gastric cancer (Park et al.,
2000a, 2000b), and leads in the mouse to the overproduction
of undifferentiated gastric cells (Lefebvre et al., 1996).
TFF1, an orphan ligand
TFF1 is a secreted peptide detected in gastric juice and urine,
suggesting possible paracrine, autocrine, and/or endocrine
functions for this protein. In the present study, we consistently
observed that the addition of exogenous recombinant TFF1,
or cellular synthesis of TFF1, leads to similar results, indicat-
ing that TFF1 signalling is active at both the paracrine and au-
tocrine levels. We sometimes observed a lower efficiency of
TFF1 activity under autocrine conditions, which was probably
due to the need for additional secretory steps. Moreover, doxy-
cycline induction of TFF1 also requires the synthesis of the
transactivator (Gossen et al., 1995). Our results call into ques-
tion the mode of transduction of extracellular TFF1 signals to
the interior of the cell. TFF1 internalization via the endosomal
pathway has been discarded as a mechanism in MCF7 human
breast cancer cells (Laurent-Matha et al., 1998), but remains
to be studied in the context of gastrointestinal cells. For several
years, it has been hypothesized that TFF1 could act by bind-
ing to specific receptors. The present study supports this hy-
pothesis. Nevertheless, despite numerous studies, to date no
canonical receptors have been identified (Thim, 1997; Ribi-
eras et al., 1998; Hoffmann et al., 2001). However, it has been
shown that TFF1 directly binds to mucins that constitute the
mucus layer lining the gastrointestinal tract (Newton et al.,
2000; Tomasetto et al., 2000). It remains to be seen if mucins
can transduce TFF1 signalling.
Materials and methods
Preparation of recombinant human TFF1
Human TFF1 was produced in yeast Pichia pastoris and purified as previ-
ously described (Kannan et al., 2001). P. pastoris were cultured in syn-
thetic Kapeli’s medium.
Cell cultures
The human HCT116 (colon), HeLa (cervix), AGS (stomach), and Jurkat (T
cell) cancer cell lines, and the rat normal intestinal epithelial cell IEC18
were obtained from the American Type Culture Collection. Cells were
grown in DME, Ham’s F12 50/50 mix, 10% FCS (AGS cells), DME supple-
mented with 0.1 U of bovine insulin per ml, 1 mM sodium pyruvate, and
either 5 or 7.5% FCS (IEC18 and HCT116 cells, respectively), or a combi-
nation of 2.5% calf serum and 2.5% FCS (HeLa cells). Jurkat cells were
grown in RPMI (Sigma-Aldrich) supplemented with 2 mM glutamine and
10% FCS. All the cells were grown in 5% CO2 at 37 C.
Stable transfection of HCT116 cells
To produce stable cell lines expressing human TFF1, two plasmids were
designed. BamHI and EcoRI/BamHI fragments ( 280 bp) corresponding to
the open reading frame of the human TFF1 cDNA (Accession no. x00474)
were inserted into the BamHI site of the pCMV-neoconstitutive expression
vector (Baker et al., 1990) and the EcoRI/BamHI sites of pUHD 10-3 doxy-
cycline inducible expression vector respectively, thus generating the
pCMV-hTFF1 and the pUHD-hTFF1 plasmids.
HCT116 cells were transfected by calcium-phosphate coprecipitation
with the Hind III-linearized pCMV-hTFF1 or the Pvu I-linearized pUHD-
hTFF1 vector. The pUHD172-1neo that encodes for the transactivator and
neomycin resistance (Gossen et al., 1995) was cotransfected with the
pUHD-hTFF1 vector. The pCMV and pUHD parental vectors were used as
negative controls. The culture medium was changed after 24 h and, on the
following day, the selection was initiated by addition of G418 (800  g/ml)
(Life Technologies, Inc.). After 2 wk, G418-resistant clones were subcloned
in 24-well plates. The TFF1 synthesis was assessed after 48 h of incubation
in serum-deprived medium (pCMV-hTFF1– and pUHD-hTFF1–transfected
clones) or serum-deprived medium supplemented with 1  g/ml of doxycy-
cline (Sigma-Aldrich) (pUHD-hTFF1–transfected clones). For each clone,
10  l of conditioned medium was analyzed by Western blot using the
p2802 anti–human TFF1 monoclonal antibody (Rio et al., 1991). Electro-
phoresis was done in tris-tricine high-resolution peptide separation mini-
gels as described (Promega). Two clones expressing TFF1 either constitu-
tively (HCT116/TFF1a and HCT116/TFF1b) or under doxycycline induction
(HCT116/iTFF1a and HCT116/iTFF1b) were selected together with corre-
sponding negative controls containing the vector alone (HCT116/CMVa
and HCT116/CMVb, and HCT116/UHDa and HCT116/UHDb).
Cell number assay
Cells were seeded on 96-well plates (5,000 cells/well) and cultured for
48 h in the presence of different concentrations of recombinant human
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incubation at 37 C for 2 h in medium containing 500  g/ml of MTT re-
agent (3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide; Sigma-
Aldrich). This assay is based on the cleavage of the tetrazolium salt by via-
ble cells. The reaction produces the accumulation of a water insoluble
formazan salt proportional to the number of living cells in the well
(Uchino et al., 2000). The formazan crystals formed were extracted with
dimethyl sulfoxide (100  l/well) and the absorbance at 570 nm was mea-
sured by a microplate spectrophotometer (Biorad Laboratories). Cells were
treated with 10  M of an unrelated peptide (GTVERTGDTGMLPDNY-
VEDI) or albumin (Fraction V; Sigma-Aldrich), as negative controls.
Cell cycle analysis
HCT 116 cells were enriched in G1 phase by a 1-h treatment with 25  M
olomoucine (Calbiochem) (Park et al., 1997). Then, cells were released in
fresh medium supplemented or not with 1  M TFF1 for 1 h. The patterns of
cell DNA content were assessed by incubating cells overnight at 4 C in a so-
lution containing 10  g propidium iodide and 1 mg/ml of RNase A in PBS.
FACS analysis
Synthesis of several proteins related to the cell cycle was studied using rab-
bit polyclonal or mouse monoclonal antibodies directed against human re-
tinoblastoma protein pRb (Pharmingen), PCNA (Dako), and cyclin D1, cy-
clin B1, p15, p16, p21, and p27 (Santa Cruz Biotechnology). Cells, fixed
overnight in 80% of cold ethanol, were centrifuged (1,200 rpm, 5 min) and
resuspended in 100  l of 1% BSA in PBS and incubated with primary anti-
bodies at 4 C overnight. Then cells were rinsed with 1% BSA in PBS, cen-
trifuged and incubated 30 min at room temperature in 100  l of 1% BSA
in PBS containing either FITC-conjugated donkey anti–rabbit IgG (H L)
(Jackson ImmunoResearch Laboratories, Inc.) or the AlexaFluor
TM 488 goat
anti–mouse IgG (H L) (Molecular Probes Europe BV). All experiments
were analyzed with a FACScan flow cytometer (Becton Dickinson). Cells
with fluorescence intensity  100 were considered as positive.
Luciferase reporter assays
Parental and stably transfected HCT116 cell lines were plated on 6-well
plates (5   10
5 cells/well) and transfected by calcium phosphate coprecip-
itation with 1  g/well of vectors containing either a specific response ele-
ment for pRb (pRb-Ta-Luc) or E2F (pE2F-Ta-Luc) (Mercury Cell Cycle Pro-
filing System; Clontech). The pTa-Luciferase (pTa-Luc) vector devoid of
response element was used as negative control. 12 h after transfection, cul-
ture medium was replaced by fresh medium containing or not 10  M of
recombinant human TFF1 and in the case of HCT116/iTFF1 cell lines the
medium was supplemented with 1  g/ml of doxycycline. After 24 h, cells
were lysed and cytosolic luciferase activity was quantified on a MicroLu-
mat LB 96P luminometer (EG&G Berthold). In all cases, an RSV- -galac-
tosidase reporter gene was cotransfected in order to quantify the transfec-
tion efficiency. Results were expressed as relative luciferase activities
compared to the luciferase activity of the empty vectors that was set at 1,
and corrected for  -galactosidase activity.
Apoptosis induction
Cells were seeded on 96-well plates at 10
3 cells/well. Apoptosis was
chemically induced by incubation for 48 h in butyrate (5 mM; HCT116
and AGS cells), C2-ceramide (50  M; IEC18 and HeLa cells), or staurospo-
rine (1  M; Jurkat cells).
A three-dimensional spheroid culture system was used to induce anchor-
age-dependent apoptosis (anoikis) in IEC18, HCT116, and AGS cells. Briefly,
5   10
4 cells per well were plated on 6-well plates coated with 1% SeaPlaque
agarose to which cells can not attach. Plates were incubated in humidified at-
mosphere at 37 C, 5% CO2 for 3 d. Then, cell aggregates were mechanically
dissociated and replated on normal 6-well plates and allowed to attach and
form colonies. After 48 h, the number of viable cells was counted.
Finally, apoptosis was induced in IEC18, HCT116, and AGS cells by
transfection with 0.25  g/well of a Bad expression plasmid (Cell Signaling
Technology, Inc.) using the Fugene
TM 6 Transfection Reagent (Boehringer).
After 12 h of incubation, cells were fed with fresh medium.
Whatever the nature of the apoptotic stimulus, experiments were per-
formed in the absence or presence of various TFF1 concentrations or in
cells expressing TFF1. Cell viability was assessed using the MTT method
(see above).
Caspase analysis
Apoptosis was assessed by measuring caspase activities with the Caspase
Substrate Set IV (Calbiochem) using the 7-amino-4 (trifluoromethyl) cou-
marin (AFC) fluorogenic substrate. This kit allows the analysis of cas-
pase-1, -2, -3, -4/5, -6, -8, and -9. The assays were conducted as specified
by the manufacturers. In brief, cells (1,0000 cells/well; 24 wells) were in-
cubated 5 min in ice-cold lysis buffer (50 mM Hepes, 100 mM NaCl, 0.1%
Chaps, 10 mM DTT, 100  M EDTA, 10% glycerol) and centrifuged at
10,000 g for 10 min at 4 C. The total protein concentration of the cytosolic
extract (supernatant) was defined using the Bradford method (Bradford,
1976). Cell lysates were then incubated with 10  M of the appropriate
substrate for 2 h, and the fluorescence was quantified by spectrofluorome-
try using an excitation wavelength of 400 nm and an emission wavelength
range of 505 nm. Caspase activity was expressed as pmol AFC per hour
per  g of total protein.
Western blot analysis of procaspase-9 processing
Apoptosis was butyrate-induced in parental and transfected HCT116 cell
lines. 48 h after TFF1 treatment (parental HCT116) or doxycycline treat-
ment of doxycycline inducible HCT116 cell lines, cells were centrifuged
(2,000 rpm), and incubated 20 min in lysis buffer (20 mM Tris, 400 mM
KCl, 20% glycerol and 2 mM DTT). After three freeze/thaw cycles in liquid
nitrogen, lysates were centrifuged (10,000 rpm). Supernatants (15  g pro-
tein) corresponding to cytosolic extracts were loaded on 10% SDS-Page
gels, electrophoresed, electrotransferred onto nitrocellulose membranes,
and analyzed using rabbit polyclonal antibody (1:2,000), allowing the de-
tection of the procaspase-9 (47 kD) and the caspase-9 (37 kD) (Cell Signal-
ling Technology). After washing (PBS 1 , 0.1% Tween 20), the blots were
incubated with a peroxidase-conjugated secondary antibody (1:2,000; Cell
Signalling Technology), washed again, and revealed using a chemilumi-
nescence substrate (NEN Life Science).
Statistical analysis
All assays were performed in triplicate. Data are means   SE and are rep-
resentative of at least three independent experiments (nine assays). Results
were analyzed by a Student’s t test using Microsoft Excel 2000 and were
considered significantly different if *P   0.05 or **P   0.01.
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